Nicotine patch
Drug21 mg
Other names: Nicoderm CQ
NCT Number: NCT01050569
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content (VLNC) cigarettes compared to 21 mg nicotine patch only and very low nicotine content cigarette only on abstinence, time to relapse and toxicant levels. The study will determine if adding nicotine replacement medication to the very low content cigarettes (VLNC) will augment treatment compared to nicotine patch only or to very low nicotine content cigarettes only.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
University of Minnesota, Duluth, Minnesota, United States
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content cigarette (VLNC) compared to the VLNC cigarette alone or 21 mg nicotine patch alone on abstinence, time to relapse and toxicant levels.
The following primary hypothesis will be tested:
Abstinence rates will be highest and the time to relapse will be the longest in the VLNC cigarettes plus nicotine patch condition compared to nicotine patch or VLNC cigarettes alone.
Other hypotheses include:
Cigarette smokers will be randomized to:
Outcome measures will include cessation assessed at the end of treatment as the primary endpoint and at 36 weeks post-treatment, time to lapse and relapse to usual brand cigarettes, and biomarkers of toxicant exposure. Predictors of abstinence and treatment response for each of the treatment conditions will be explored.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
21 mg
Other names: Nicoderm CQ
Cigarette where the tobacco contains <0.1 mg of nicotine yield.
Other names: Quest 3, Xodus
21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
Other names: Nicoderm CQ, Quest 3, Xodus
Time frame: 12 week
Cotinine and carbon monoxide (CO) verified point prevalence abstinence
Time frame: 36 weeks
CO- and cotinine-verified point prevalence abstinence
Time frame: 6 weeks
Time frame: 26 weeks
University of Minnesota
Other
Innovative Interventions for Smoking Cessation: Comparison of Very Low Nicotine Content Cigarettes Plus Nicotine Patch; Very Low Nicotine Content Cigarettes Alone or Nicotine Patch Alone
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737288
Behavior, Chemically-Induced Disorders
Izmir, Turkey (Türkiye)
View Trial DetailsNCT03950427
Behavior, Chemically-Induced Disorders
San Francisco, California, United States
View Trial DetailsNCT03922360
Behavior, Chemically-Induced Disorders
Burlington, Vermont, United States
View Trial DetailsNCT05729243
Alcohol Use Disorder, Alcohol-Related Disorders
Toronto, Ontario, Canada
View Trial Details